Varicella zoster immune globulin (human) - Biologic Drug Details

Summary for varicella zoster immune globulin (human)

Tradenames:	1
High Confidence Patents:	0
Applicants:	1
BLAs:	1
Suppliers: see list	2
Recent Clinical Trials:	See clinical trials for varicella zoster immune globulin (human)

Recent Clinical Trials for varicella zoster immune globulin (human)

Identify potential brand extensions & biosimilar entrants

Sponsor	Phase
Cangene Corporation
National Eye Institute (NEI)	Phase 2

See all varicella zoster immune globulin (human) clinical trials

Note on Biologic Patents

Matching patents to biologic drugs is far more complicated than for small-molecule drugs.

DrugPatentWatch employs three methods to identify biologic patents:

1. Brand-side disclosures in response to biosimilar applications

These patents were identified from disclosures by the brand-side company, in response to a potential biosimilar seeking to launch. They have a high certainty of blocking biosimilar entry. The expiration dates listed are not estimates — they're expiration dates as indicated by the brand-side company.

2. General brand-side disclosures

These patents were identified from searching drug labels and other general disclosures from the brand-side company. This list may exclude some of the patents which block biosimilar launch, and some of these patents listed may not actually block biosimilar launch. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

3. Patents from broad patent text search

For completeness, these patents were identified by searching the patent literature for mentions of the branded or ingredient name of the drug. Some of these patents protect the original drug, whereas others may protect follow-on inventions or even inventions casually mentioning the drug. The expiration dates listed for these patents are estimates, based on the grant date of the patent.

1) High Certainty: US Patents for varicella zoster immune globulin (human) Derived from Brand-Side Litigation

No patents found based on brand-side litigation

2) High Certainty: US Patents for varicella zoster immune globulin (human) Derived from Company Disclosures

No patents found based on company disclosures

3) Low Certainty: US Patents for varicella zoster immune globulin (human) Derived from Patent Text Search

No patents found based on company disclosures

Varicella zoster immune globulin (human) Market Analysis and Financial Projection Experimental

Market Dynamics and Financial Trajectory for Varicella Zoster Immune Globulin (Human)

Introduction

Varicella zoster immune globulin (VZIG), also known as human varicella-zoster immune globulin, is a biologic drug that plays a crucial role in preventing and reducing the severity of varicella-zoster virus (VZV) infections in high-risk individuals. This article delves into the market dynamics and financial trajectory of this important therapeutic agent.

Market Size and Growth

The global human varicella-zoster immunoglobulin market has been experiencing steady growth. As of 2024, the market size was valued at USD 169.9 million. Projections indicate that this market is expected to reach USD 215 million by 2031, exhibiting a Compound Annual Growth Rate (CAGR) of 3.4% during this period[1].

Driving Factors

Several factors are driving the growth of the VZIG market:

Increasing Incidence of VZV Infections

The rising incidence of varicella-zoster virus infections, particularly among high-risk populations such as immunocompromised individuals, pregnant women, and premature babies, is a significant driver. These groups are more susceptible to severe complications from VZV infections, making VZIG a critical preventive measure[1][4].

Growing Demand for Effective Prophylactic and Therapeutic Measures

There is an increasing demand for effective prophylactic and therapeutic measures to manage VZV infections. VZIG, with its proven efficacy in reducing the severity and preventing varicella infections, is meeting this demand effectively[1][4].

Indications and Usage

VZIG is indicated for preventing and reducing the severity of chickenpox (varicella zoster virus) infections in high-risk individuals within 4 days of exposure. This includes:

High-Risk Populations

• Immunocompromised patients
• Pregnant women
• Premature babies
• Babies younger than 1 year of age
• Individuals for whom the varicella vaccine is contraindicated[2][4][5].

Mechanism of Action

VZIG provides passive immunization by administering antibodies derived from human plasma. These antibodies bind to proteins on the varicella virus, thereby preventing or reducing the severity and progression of varicella infections. The drug is prepared from pools of healthy human donors' plasma and is available as an intramuscular injection[2][4].

Pharmacokinetics

The pharmacokinetics of VZIG are crucial for its efficacy:

Absorption and Distribution

Following intramuscular administration, varicella antibodies are detectable within 2-3 days, with peak levels occurring within 3-7 days. The drug achieves nearly 100% bioavailability and persists for 6 weeks or longer[2][4].

Half-Life

The half-life of VZIG is approximately 18-24 days following intravenous administration and 24-30 days following intramuscular administration[2][4].

Administration and Dosage

VZIG is administered intramuscularly, with dosing based on the patient's weight. It is available in 125 IU per 1.2 mL vials. Administration should be initiated as soon as possible after exposure and can be given up to 10 days post-exposure[4][5].

Clinical Outcomes and Efficacy

Studies and clinical evaluations have demonstrated that VZIG is effective in preventing or modifying clinical illness in susceptible, immunocompromised patients. Early administration, especially in pregnant women, has been shown to decrease maternal morbidity and reduce the incidence and morbidity of varicella-zoster in preterm newborns and infants exposed in utero[3][4].

Adverse Effects and Safety

VZIG has a favorable safety profile with minimal adverse reactions and toxicity. However, it is important to note that the drug is made from donated human blood, and although the risk is low, there is a potential for transmitting viruses. Patients should avoid live virus vaccines for 3 months after receiving VZIG[5].

Economic Considerations

The cost of VZIG administration can be substantial, with prices ranging from approximately $75 per 125 units to $375 for individuals over 40 kg (88 lbs) of body weight for the maximum recommended dose. Despite the costs, the benefits of preventing severe varicella infections and their complications make VZIG a valuable therapeutic option[3].

Interprofessional Team Approach

The administration of VZIG is best managed through an interprofessional team approach, involving physicians, advanced practice practitioners, nursing staff, and pharmacists. This collaborative approach ensures early recognition of exposure, appropriate dosing, and effective communication with patients and caregivers[4].

Market Trends and Future Outlook

The market for VZIG is expected to continue growing due to the increasing awareness of the importance of preventive measures against VZV infections. Advances in manufacturing processes and the expansion of donor screening programs are likely to improve the availability and efficacy of VZIG.

Regulatory Environment

Regulatory approvals and guidelines from bodies like the FDA and CDC play a crucial role in the market dynamics. The FDA's approval of VZIG in 2012 under the name VariZIG has been instrumental in its widespread adoption[2][3].

Competitive Landscape

While VZIG is a niche product, its unique position in the market as a post-exposure prophylactic and therapeutic agent ensures a stable demand. The competitive landscape is characterized by a few key players, with VariZIG being a prominent brand[2].

Key Takeaways

• The global human varicella-zoster immunoglobulin market is projected to grow from USD 169.9 million in 2024 to USD 215 million by 2031.
• The market is driven by the increasing incidence of VZV infections and the growing demand for effective prophylactic measures.
• VZIG is indicated for high-risk populations, including immunocompromised individuals, pregnant women, and premature babies.
• The drug provides passive immunization and has a favorable safety profile.
• Early administration and an interprofessional team approach are critical for maximizing efficacy.
• Economic considerations, including the cost of administration, are significant but justified by the benefits of preventing severe infections.

FAQs

What is the expected market size of the human varicella-zoster immunoglobulin market by 2031?

The human varicella-zoster immunoglobulin market is expected to reach USD 215 million by 2031[1].

What is the CAGR of the human varicella-zoster immunoglobulin market?

The market is expected to exhibit a CAGR of 3.4% by 2031[1].

Who are the high-risk individuals for whom VZIG is indicated?

VZIG is indicated for immunocompromised patients, pregnant women, premature babies, and babies younger than 1 year of age, as well as individuals for whom the varicella vaccine is contraindicated[2][4][5].

How is VZIG administered?

VZIG is administered intramuscularly, with dosing based on the patient's weight, and can be given up to 10 days post-exposure[4][5].

What are the potential adverse effects of VZIG?

VZIG has a favorable safety profile with minimal adverse reactions and toxicity, although there is a low risk of transmitting viruses from donated human blood[5].

How long does the passive protection provided by VZIG last?

The passive protection provided by VZIG generally lasts for 6 weeks or longer, with peak antibody levels occurring within 3-7 days of administration[2][4].

Sources

1. Proficient Market Insights: Human Varicella-Zoster Immunoglobulin Market.
2. DrugBank: Human varicella-zoster immune globulin.
3. CDC: Recommendations of the Immunization Practices Advisory Committee (ACIP) on the use of varicella-zoster immune globulin (VZIG).
4. NCBI Bookshelf: Varicella-Zoster Immune Globulin - StatPearls.
5. Mayo Clinic: Varicella-zoster immune globulin (intramuscular route).